Suppression of TGF beta and Angiogenesis by Type VII Collagen in Cutaneous SCC




Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kahari VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O'Toole EA

PublisherOXFORD UNIV PRESS INC

2016

JNCI: Journal of the National Cancer Institute

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

JNCI-J NATL CANCER I

ARTN djv293

108

1

11

0027-8874

DOIhttps://doi.org/10.1093/jnci/djv293(external)



Conclusions: Type VII collagen suppresses TGF beta signaling and angiogenesis in cutaneous SCC. Patients with RDEB SCC may benefit from anti-angiogenic therapy.



Last updated on 2024-26-11 at 17:47